Abstract
The kinetics of Yttrium-90 (Y-90) in bone of mice was investigated in combination with edetate calcium disodium (CaNa2EDTA). One group of mice were intraperitoneally administered 37.5 mg/ kg CaNa2EDTA or 0.9% NaCl as a control at 1, 22, 34, 46, 58, 70, 82, 94, 154 and 166 h after injection of Y-90 acetate (post-administration), and the biodistribution was studied at 3, 24, 72, 120 and 168 h postinjection of Y-90 acetate. No difference between the post-CaNa2EDTA-treated mice and the control was demonstrated in the radioactivity in the bone. A decrease in radioactivity in the liver and kidneys was accelerated, and the radioactivity was lower than the control at 120 h postinjection. The other group of mice were also given the same dose of chelator at 12 h and 1 h preinjection of Y-90 acetate and at 1, 22, 34, 46, 58, 70, 82, 94, 154 and 166 h after injection of Y-90 acetate (pre- and post-administration), the radioactivity in bone at 3 h postinjection was significantly lower than in the control (24.4 ± 3.92% ID/g vs. 31.7 ± 2.26% ID/g, p < 0.05), but the decrease was not sequential. A significant reduction in radioactivity in the blood, kidneys and liver was demonstrated at 3 h, 72 h and 72 h postinjection. In conclusion, the CaNa2EDTA with the administration schedule employed here cannot chelate the Y-90 from bone but the free Y-90 before deposition into bone.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hnatowich DJ, Chinol M, Siebeker DA, Gionet M, Griffin T, Doherty PW, et al. Patient biodistribution of intraperitoneally administered yttrium-90 labeled antibody.J Nucl Med 29: 1428–1434, 1988.
Sharkey R, Kaltovich FA, Shih LB, Fand I, Govelitz G, Goldenberg DM. Radioimmunotherapy of human colonic cancer xenografts with yttrium-90 labeled monoclonal antibodies to carcinoembryonic antigen.Cancer Res 48: 3270–3275, 1988.
MacDonald NS, Nusbaum RE, Alexander GV, Ezmirlian F, Spain P, Rounds DE. The skeletal deposition of yttrium.J Biol Chem 195: 837–841, 1952.
Jowsey J, Sissons HA, Vaughan J. The site of deposition of Y-91 in the bones of rabbits and dogs.J Nucl Energy 2: 168–176, 1956.
Jowsey J, Rowland RE, Marshall JH. The deposition of the rare earths in bone.Rad Research 8: 490–501, 1958.
Durbin PW. Metabolic characteristics within a chemical family.Health Phys 2: 225–238, 1960.
Vaughan JM, Tutt ML. Use of ethylene diamine tetraacetic acid (versene) for removing fission products from the skelton.Lancet 2: 856–859, 1953.
Rowlinson-Busza G, Snook D, Epenetos AA.90Y-labeled antibody uptake by human tumor xenografts and the effect of systemic administration of EDTA.Int J Radiation Oncology Biol Phys 28: 1257–1265, 1994.
Stewart JSW, Hird V, Snook D, Dhokia B, Sivalapenko G, Hooker G, et al. Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer.J Clin Oncol 8: 1941–1950, 1990.
Watanabe N, Oriuchi N, Endo K, Inoue T, Kuroki M, Matsuoka Y, et al. Use of CaNa2EDTA for improvement of radioimmunodetection and radioimmunotherapy with indium-111 and yttrium-90-DTPA-anti-CEA MAbs in nude mice bearing human colorectal cancer.J Nucl Med (in press)
Klaassen CD. Toxicology.In Goodman and Gilman’s The Pharmacological Basis of Therapeutics, Goodman Gilman A, Rall TW, Nies AS, Taylor P (eds.), 8th ed., New York, Pergamon Press, Inc., pp. 1592–1614, 1990.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Watanabe, N., Oriuchi, N., Tanada, S. et al. Effect of edetate calcium disodium on yttrium-90 activity in bone of mice. Ann Nucl Med 13, 397–400 (1999). https://doi.org/10.1007/BF03164933
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03164933